Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells $1,030,705.00 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos sold 15,857 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $65.00, for a total transaction of $1,030,705.00. Following the completion of the transaction, the executive vice president owned 58,555 shares of the company’s stock, valued at approximately $3,806,075. This represents a 21.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Callos also recently made the following trade(s):

• On Thursday, April 30th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The shares were sold at an average price of $63.26, for a total transaction of $948,900.00.
• On Wednesday, April 15th, Andrew Callos sold 7,449 shares of Cytokinetics stock. The shares were sold at an average price of $66.02, for a total transaction of $491,782.98.
• On Wednesday, March 18th, Andrew Callos sold 1,930 shares of Cytokinetics stock. The shares were sold at an average price of $62.07, for a total transaction of $119,795.10.
• On Tuesday, March 17th, Andrew Callos sold 8,542 shares of Cytokinetics stock. The shares were sold at an average price of $62.15, for a total transaction of $530,885.30.
• On Monday, March 16th, Andrew Callos sold 1,709 shares of Cytokinetics stock. The shares were sold at an average price of $61.03, for a total transaction of $104,300.27.
• On Monday, March 9th, Andrew Callos sold 2,582 shares of Cytokinetics stock. The shares were sold at an average price of $60.72, for a total transaction of $156,779.04.
• On Thursday, March 5th, Andrew Callos sold 26,000 shares of Cytokinetics stock. The shares were sold at an average price of $61.87, for a total transaction of $1,608,620.00.
• On Thursday, February 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The shares were sold at an average price of $61.93, for a total transaction of $928,950.00.

Cytokinetics Price Performance

CYTK opened at $74.84 on Thursday. The firm has a fifty day moving average price of $64.13 and a 200 day moving average price of $63.75. Cytokinetics, Incorporated has a 1 year low of $29.31 and a 1 year high of $80.20. The stock has a market cap of $9.30 billion, a P/E ratio of -10.94 and a beta of 0.38.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.67). The firm had revenue of $19.36 million during the quarter, compared to analyst estimates of $8.52 million. During the same quarter in the prior year, the firm earned ($1.36) earnings per share. The business’s revenue for the quarter was up 1112.5% on a year-over-year basis. Equities analysts expect that Cytokinetics, Incorporated will post -6.31 EPS for the current year.

Institutional Investors Weigh In On Cytokinetics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CYTK. Woodline Partners LP increased its holdings in Cytokinetics by 676.1% in the 3rd quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock worth $90,559,000 after acquiring an additional 1,435,422 shares in the last quarter. Norges Bank purchased a new stake in shares of Cytokinetics during the fourth quarter worth $51,281,000. Deep Track Capital LP grew its holdings in shares of Cytokinetics by 17.8% during the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock worth $236,328,000 after buying an additional 650,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Cytokinetics by 151,987.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 565,765 shares of the biopharmaceutical company’s stock worth $35,949,000 after buying an additional 565,393 shares in the last quarter. Finally, Foresite Capital Management IV LLC purchased a new stake in shares of Cytokinetics during the third quarter worth $25,188,000.

Wall Street Analyst Weigh In

CYTK has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Cytokinetics in a report on Monday, April 20th. Stifel Nicolaus set a $108.00 price target on shares of Cytokinetics in a report on Wednesday. Mizuho boosted their price target on shares of Cytokinetics from $84.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, March 18th. Bank of America reissued a “neutral” rating on shares of Cytokinetics in a report on Wednesday, February 25th. Finally, Leerink Partners reissued an “outperform” rating on shares of Cytokinetics in a report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $96.75.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Topline pivotal Phase‑3 success — the ACACIA‑HCM trial of aficamten (non‑obstructive HCM) met both dual primary endpoints with supportive secondary data, materially de‑risking the program and boosting commercial/regulatory prospects. Read More.
• Positive Sentiment: Early commercial traction and revenue beat — MYQORZO U.S. launch showed ~275 HCPs prescribing to ~680 patients in Q1 and generated ~$4.8M in partial‑quarter net product revenue; company reported Q1 revenue of $19.36M (well above consensus) and ~$1.1B cash on hand to fund launch. Read More.
• Positive Sentiment: Analyst momentum — several firms raised price targets and reiterated buy/outperform views following the trial & launch updates, supporting upside sentiment. Read More.
• Neutral Sentiment: Q1 EPS in line but losses continue — GAAP loss of ($1.67) matched estimates even as revenue surprised to the upside, highlighting strong top‑line launch execution but ongoing operating losses while scaling. Read More.
• Neutral Sentiment: Insider selling under 10b5‑1 plans — EVPs Andrew Callos and Fady Malik disclosed multi‑sale transactions executed via Rule 10b5‑1 plans; these are planned sales (not necessarily negative on fundamentals) but can prompt near‑term investor attention. Read More.
• Negative Sentiment: Planned $650M common stock offering — the proposed underwritten offering would fund commercialization and development but introduces near‑term dilution risk and is likely the main driver of selling pressure following the earlier rally. Read More.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.